User:Mr. Ibrahem/Casirivimab/imdevimab
 | |
| Combination of | |
|---|---|
| Casirivimab | Monoclonal antibody against SARS-CoV-2 |
| Imdevimab | Monoclonal antibody against SARS-CoV-2 |
| Clinical data | |
| Trade names | REGEN-COV, Ronapreve |
| Other names | REGN-COV2 |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Intravenous, subcutaneous injection |
| Legal status | |
| Legal status | |
Casirivimab/imdevimab, sold under the brand name REGEN-COV among others, is a medication used to treat and prevent COVID-19.[6] As treatment it is used in mild to moderate disease in those at high risk.[6] It works much less well in those with the Omicron variant.[7][8] It is given by injection under the skin or into a vein.[6]
Common side effects include infusion reaction and redness at the site of injection.[6] Other side effects may include anaphylaxis, fever, and breathing problems.[6] While it may be used in pregnancy, safety is unclear.[6] It is two monoclonal antibodies, casirivimab (REGN10933) and imdevimab (REGN10987) which bind to the virus.[4][9]
The combination is available under an emergency use authorization in the United States as of 2021.[6] It is approved for medical use in Australia, the UK, and Japan.[10][11][1] In the United States the government has purchased doses at 2,100 USD each, which they provide free.[12] In Germany it was purchased for about €2,000 per dose.[13]
References[edit]
- ^ a b c "Ronapreve". Therapeutic Goods Administration (TGA). 18 October 2021. Archived from the original on 23 October 2021. Retrieved 22 October 2021.
- ^ "COVID-19 treatment: Roche Products Pty Ltd, casirivimab + imdevimab (Ronapreve)". Therapeutic Goods Administration (TGA). 15 October 2021. Archived from the original on 24 October 2021. Retrieved 22 October 2021.
- ^ "Summary of Product Characteristics for Ronapreve". Medicines and Healthcare products Regulatory Agency (MHRA). 20 August 2021. Archived from the original on 30 August 2021. Retrieved 29 August 2021.
- ^ a b "Casirivimab injection, solution, concentrate Imdevimab injection, solution, concentrate REGEN-COV – casirivimab and imdevimab kit". DailyMed. Archived from the original on 4 January 2021. Retrieved 18 March 2021.
- ^ "Japan becomes first country to approve Ronapreve (casirivimab and imdevimab) for the treatment of mild to moderate COVID-19". Roche (Press release). 20 July 2021. Archived from the original on 24 July 2021. Retrieved 29 August 2021.
- ^ a b c d e f g h i "Casirivimab and Imdevimab Monograph for Professionals". Drugs.com. Archived from the original on 21 October 2021. Retrieved 6 November 2021.
- ^ Kozlov, Max (21 December 2021). "Omicron overpowers key COVID antibody treatments in early tests". Nature. doi:10.1038/d41586-021-03829-0. Archived from the original on 22 December 2021. Retrieved 23 December 2021.
- ^ "Statement on Therapies for High-Risk, Nonhospitalized Patients". COVID-19 Treatment Guidelines. Archived from the original on 7 January 2022. Retrieved 6 January 2022.
- ^ "Casirivimab + imdevimab". SPS - Specialist Pharmacy Service. 26 December 2020. Archived from the original on 6 November 2021. Retrieved 6 November 2021.
- ^ "Regulatory approval of Ronapreve". Medicines and Healthcare products Regulatory Agency (MHRA). 20 August 2021. Archived from the original on 30 August 2021. Retrieved 29 August 2021.
- ^ Tsukimori, Osamu (5 November 2021). "Japan OKs use of 'antibody cocktail' to prevent COVID-19". The Japan Times. Archived from the original on 6 November 2021. Retrieved 6 November 2021.
- ^ Jarvis, Jacob (12 October 2021). "Fact Check: Regeneron monoclonal antibody costs government $2,100 per dose". Newsweek. Archived from the original on 4 November 2021. Retrieved 6 November 2021.
- ^ "Coronavirus: Germany to use new antibody-based drug". DW. 24 January 2021. Archived from the original on 8 October 2021. Retrieved 30 September 2021.